Regulatory Pathway as Capital Structure
How FDA Classification and Coverage Determine Your Cap Table
The learning framework
The indication that cost three rounds
A team has a device that works. It can be submitted through 510(k) with a narrow indication, or through PMA with the broad one that matches what the technology actually does and the market they actually want. They choose the broad indication. It is the better product, it is the larger opportunity, and the clinical logic is sound. It also means a pivotal trial, several additional years, and two more financings than the narrow path would have required. They get approved. The product is what they said it would be. By the time an acquirer is at the table, the founding team holds a fraction of what the narrower path would have left them, and the acquirer is paying for the approval rather than for the conviction it took to pursue it. Neither path was wrong. What is notable is that the choice was made as a clinical and market decision, discussed with clinical and market advisors, and never once modeled as a capital decision. Nobody in the room asked how many more times they would have to raise.
Why the pathway is treated as a compliance question
Regulatory strategy is delegated. It goes to a consultant, a regulatory affairs professional, or a vice president hired to own it, and the founders reasonably conclude that specialists should handle specialist work. That is correct for the submission. It is wrong for the decision. The specialist optimizes for approval. They will tell you accurately what each pathway requires and what it is likely to cost. They are not asked, and are not usually positioned to answer, what the resulting capital requirement does to the cap table, how many financings it implies, or where founder ownership lands by the time approval arrives. The same delegation produces a second error. Clearance and coverage are treated as one topic. They are separate systems with separate decision makers, separate evidence requirements, and separate timelines. A device can be cleared and never paid for. That outcome is a structural failure rather than a regulatory one, and it is visible years in advance to anyone who looks.
Pathway chosen as a capital decision
Healthcare innovators who complete this evolution select a pathway with the clinical case, the market case, and the capital case on the table at once. They can state how many financings their chosen path implies and what that does to their position. They know whether a coverage pathway exists before they commit to an evidence plan built only for the agency. They can anticipate how an acquirer will price the regulatory and coverage risk their company is carrying, because they have seen how that pricing works. They still hire the regulatory specialist. They now know what to ask.
By the end of this evolution, you will be able to:
Map pathway to capital requirement to dilution
Trace the line from product classification through capital requirement, financing count, and founder ownership at exit. Run the same product down two pathways and see the difference in what you hold at the end.
Compare pathways as structural choices
Understand what 510(k), De Novo, PMA, and the IND to NDA route each demand in evidence, time, and capital, and what each does to the shape of a company. Understand how a device pivotal study and a phased clinical program differ in structure, duration, and the number of financings each implies, so that you can read either one. Recognize when a narrower initial indication is the structurally stronger choice and when it is not.
Separate clearance from coverage
Distinguish the agency's question from the payer's question. Understand why approval to market and a decision to pay are made by different parties on different evidence, and why a product can succeed at one and fail at the other.
Understand what evidence each audience requires
Compare what a regulator needs to see with what a payer needs to see and what an acquirer needs to see. Design an evidence plan that serves more than one of them rather than building for the agency and starting over for the payer.
Evaluate the existing code and new code decision
Understand the structural difference between a product that fits an established payment pathway and one that requires a new one. Recognize what the second choice costs in time and capital, and when it is nonetheless correct.
Understand how acquirers price regulatory and coverage risk
Learn how the other side of the table adjusts for a pending submission, an unresolved coverage question, or a post-market obligation. Understand that this risk is priced into terms and structure, not only into the headline number.
Time a raise against regulatory milestones
Identify which milestones move valuation and which do not, and understand why raising immediately before a readout and immediately after it produce very different outcomes.
Structure a clinical study as a capital event
The trial is usually the largest single expenditure before revenue. Understand CRO contract structures and where cost escapes them: change orders, pass-through costs, and scope definitions written loosely enough to be reinterpreted later. Understand site selection and enrollment projection as financial variables, and why a study that enrolls slowly is a financing problem before it is a schedule problem.
Why this matters
Recommended for
Healthcare innovators navigating:
Faculty who understand the process move through it faster.
Academic medical centers, research universities, and health systems sponsor cohorts so that inventors arrive at the office of technology transfer prepared: complete disclosures, clean assignment records, and realistic expectations about pathway and timeline. Cohort training is available for faculty, residents, and research staff, with CME.
Learn more about institutional cohorts →How to get started
Your path to becoming a Certified Professional Entrepreneur
Reserve your seat
Your deposit reserves a place in the cohort. Twenty seats. No application, no admissions committee, no waiting on a decision.
Begin the evolutions
Structured online learning you work through on your own schedule. Lectures run under fifteen minutes. Each evolution carries reading, supporting material, working tools, and case studies drawn from real transactions.
Join the live sessions
Live discussion sessions on Zoom, facilitated by Chris and Christos. Not recorded. This is where the material meets your actual situation, and where the cohort becomes a network.
Continue your structural training
Answers that help you decide with confidence
Your regulatory pathway decides how many times you will raise.